Examining the effects of living learning programs on first year success of undergraduates

This dissertation examines the relationship between living learning programs (LLPs) and student success at Boston University, a large, private research institution. The focus of this research was to better understand the distinctions between different types of living learning program formats (honors, academic, and special interest) and traditional housing in terms of the types of students they attract and what relationship they have with academic performance, retention, and student perception. Using the conceptual frameworks provided by Astin’s “I-E-O” model and Tinto’s longitudinal model of student departure, a mixed method design employing both quantitative (binary logistic and linear regression) and qualitative (interviews with LLP program faculty, staff, and student advisors) components was used. Results indicate that there were significant differences in student characteristics, academic performance, and perception between LLP participants and students in traditional housing. LLP participation was found to be positively related to retention, academic success and a student’s evaluation of the overall environment of the University. Academic LLP participation was linked to increased retention and first year cumulative GPA, while honors LLP participants were more inclined to rate their overall experience as excellent. These findings demonstrate that LLP format and composition are important in evaluating how these programs impact first year students. While research was limited to the students enrolled at a single institution, this study provides information about LLPs with varying level of academic integration, which can be useful to administrators looking to establish or review LLP programs on their own campus

An Educational Program for Blind Infants

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68635/2/10.1177_002246696900300201.pd

Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases.

OBJECTIVES: We sought to determine the clinical spectrum, survival, and long-term functional outcome of a cohort of pediatric patients with mitochondrial diseases and to identify prognostic factors. METHODS: Medical charts were reviewed for 73 children diagnosed between 1985 and 2005. The functional status of living patients was assessed prospectively by using the standardized Functional Independence Measure scales. RESULTS: Patients fell into 7 phenotypic categories: neonatal-onset lactic acidosis (10%), Leigh syndrome (18%), nonspecific encephalopathy (32%), mitochondrial (encephalo)myopathy (19%), intermittent neurologic (5%), visceral (11%), and Leber hereditary optic neuropathy (5%). Age at first symptoms ranged from prenatal to 16 years (median: 7 months). Neurologic symptoms were the most common (90%). Visceral involvement was observed in 29% of the patients. A biochemical or molecular diagnosis was identified for 81% of the patients as follows: deficiency of complex IV (27%), of pyruvate dehydrogenase or complex I (25% each), of multiple complexes (13%), and of pyruvate carboxylase (5%) or complexes II+III (5%). A mitochondrial DNA mutation was found in 20% of patients. At present, 46% of patients have died (median age: 13 months), 80% of whom were 5 years (n = 32), 62% had Functional Independence Measure quotients of >0.75. CONCLUSIONS: Mitochondrial diseases in children span a wide range of symptoms and severities. Age at first symptoms is the strongest predictor mortality. Despite a high mortality rate in the cohort, 62% of patients aged >5 years have only mild impairment or normal functional outcome

Intermittent peripheral weakness as the presenting feature of pyruvate dehydrogenase deficiency.

Two unrelated children presenting with episodic isolated peripheral weakness were found to have pyruvate dehydrogenase (PDH) deficiency (OMIM 312170) due to previously undescribed mutations (Pro250Thr, Arg88Cys) in the gene for the E1alpha subunit (PDHA1). Taken in context with the literature, these patients suggest that acute weakness initially resembling Guillain-Barre syndrome is a potentially reversible and probably underdiagnosed manifestation of PDH deficiency and that peripheral nerve function should be evaluated in PDH-deficient patients

Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes

AbstractObjectiveTo evaluate the physical compatibility and chemical stability of mixtures of magnesium sulphate and lidocaine in order to determine the feasibility of manufacturing a prefilled syringe combining these two drugs for use as an intramuscular (IM) loading dose for eclampsia prevention and/or treatment. This ready-to-use mixture will provide a more tolerable and accessible route of administration appropriate for widespread use.MethodsPhysical compatibility (pH, colour, and formation of precipitate) and chemical stability (maintaining > 90% of initial concentrations) of mixtures of MgSO4, using both commercially available MgSO4 (50%) and MgSO4 reconstituted from salt (61%), with lidocaine hydrochloride (2%) were evaluated every 14 days over six months. The concentration of lidocaine was determined by a stability indicating high performance liquid chromatographic method, while the concentration of magnesium was determined by an automated chemistry analyzer.ResultsNo changes in pH, color or precipitates were observed for up to 6 months. The 95% confidence interval of the slope of the curve relating concentration to time, determined by linear regression, indicated that only the admixtures of commercially-available magnesium sulfate and lidocaine as well as the 61% magnesium sulfate solution (reconstituted from salt) maintained at least 90% of the initial concentration of both drugs at 25°C and 40°C at 6 months.ConclusionsCommercially available MgSO4 and lidocaine hydrochloride, when combined, are stable in a pre-filled syringe for at least six months in high heat and humidity conditions. This finding represents the first step in improving the administration of magnesium sulphate in the treatment and prevention of eclampsia in under-resourced settings